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Abstract
Introduction: Pheochromocytoma is a rare cause of hypertension but it could have severe consequences if not
recognized and treated appropriately. The association of pheochromocytoma and thrombosis is even rarer but
significantly increases management complexity, morbidity and mortality. To the best of our knowledge, this is the
first report of a patient with pheochromocytoma presenting with left axillary arterial and intracardiac thrombus.
Case presentation: A 47-year-old Caucasian woman with a past medical history of hypertension presented for
medical attention with left arm numbness. Doppler ultrasound showed an obstructing thrombus in her left axillary
artery. She had symptom resolution after stent placement in her left axillary artery. A subsequent echocardiogram
demonstrated a large intracardiac mass and abdominal computed tomography revealed a 7 cm mass between her
spleen and left kidney. Labile blood pressure was noted during admission and she had very high levels of plasma
and 24-hour urine catecholamines and metanephrines tests. A (123)I- metaiodobenzylguanidine scan showed
intense uptake in the left abdominal mass. After adequate alpha blockage with phenoxybenzamine, laparoscopic
tumor resection was performed without complications. She had normal metanephrines and complete symptom
resolution afterwards. The intracardiac mass also disappeared with anticoagulation. All other endocrine laboratory
abnormalities returned to normal after surgery.
Conclusion: Arterial and ventricular thrombosis occurring in patients with pheochromocytoma is rare. A multidisciplinary approach is necessary in caring for this type of patient. Catecholamines likely contributed to the
development of thrombosis in our patient. Early recognition of pheochromocytoma is the key to improving
outcome.

Introduction
Pheochromocytoma is a rare disease occurring in less
than 0.2 percent of patients with hypertension [1,2]. The
classic presentation includes episodic hypertension, headaches and palpitations. However, many patients may have
atypical presentations which often delay diagnosis. Even
with classical presentations, the diagnosis is often missed
for a number of years unless the patient is evaluated in a
center experienced in this disease. Pheochromocytoma
can have devastating consequences if not recognized and
treated appropriately. Thrombolic events have been
reported rarely in patients with pheochromocytoma and
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the exact mechanism of thrombosis is unclear [3-8]. Here
we report a patient with pheochromocytoma presenting
with a left axillary arterial and intracardiac thrombus.

Case presentation
A 47-year-old Caucasian woman with a past medical
history of hypertension presented to a local hospital for
acute onset of numbness of her left arm in May 2007. A
left axillary arterial thrombus was identified on Doppler
ultrasound. Subsequently, our patient underwent left
axillary artery stent placement with complete symptom
resolution. To identify the source of the thrombus an
echocardiogram was performed, which revealed a large
mobile mass adherent to the anterior apical region of
her left ventricle. The left ventricle ejection fraction was
normal at 60%. The intracardiac mass was thought to be
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a thrombus and anticoagulation was initiated to prevent
further embolic events. Possible cancer-induced thrombosis was suspected and a computed tomography (CT)
scan of her chest, abdomen and pelvis was obtained.
This showed a 7 × 8 cm complex mass between the
upper pole of her left kidney and her spleen as well as a
3 cm nodule in the right lower lobe of her lung. A total
body positron emission tomography (PET) scan revealed
increased uptake in the abdominal mass as well as the
lung nodule, which raised the question of metastatic disease. Initially, renal cell carcinoma was considered the
most likely diagnosis and surgery was scheduled to take
place following dissolution of the intracardiac thrombus.
However, while still hospitalized for anticoagulation
therapy, our patient had multiple hypertensive episodes
with a blood pressure as high as 223/139 mmHg. This
prompted a 24-hour urine collection for catecholamine
and metanephrine tests. Her 24-hour urine metanephrine and normetanephrine levels were significantly elevated at 18160 μg (normal range: 19-140 μg), and 7742
μg (normal range: 52-310 μg) respectively. Her 24-hour
urine epinephrine level was 756 μg (normal range: 2-24
μg) and norepinephrine was 1161 μg (normal range: 15199 μg). Her 24-hour urine vanillylmandelic acid (VMA)
was also elevated at 46.6 μg (normal range: < 6 μg). She
was then referred to our endocrine clinic for further
management.
A review of her previous history revealed multiple
“spells” occurring over the last five years. During these
episodes, our patient experienced palpitations, a heavy
pounding heart beat and a sensation of “my heart jumping out of my chest”. They were accompanied by cold
sweats and right-sided headaches. Occasionally, a leftsided burning sensation of the chest along with nausea
and vomiting would accompany the headaches. The
“spells” were sometimes associated with bending over or
lying on her right side. Interestingly, these episodes
occurred more often between 10 am and 11 am. The
frequency of the spells had increased to almost daily
over the two weeks prior to presentation. Normally her
“spells” lasted only for a few seconds to a few minutes
then disappeared completely. Her blood pressure has
been normal until 2005 and she only started to take
hydrochlorothiazide and lisinopril in 2006. During her
“spell” at the outside hospital, it was noted that she was
very hypertensive with a systolic blood pressure of more
than 230 mmHg, but her blood pressure returned to
baseline after the spell passed.
Her previous studies included a normal thyroid scan.
Her non-specific symptoms were attributed to acid
reflux. Her hypertension was treated with atenolol, lisinopril and hydrochlorothiazide prior to admission to the
outside hospital. She does not have any other chronic
illness. Her medication at presentation to our clinic
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included atenolol, hydrochlorothiazide, Plavix (clopidogrel), lisinopril, Prilosec (omeprazole), potassium chloride, and warfarin. She was on an oral contraceptive
which was discontinued after her hospital admission.
Her social history is unremarkable. Both of her parents
have hypertension; otherwise there is no family history
of multiple endocrine neoplasia type 2, Von Hippel-Lindau disease, neurofibromatosis, pheochromocytoma,
thyroid cancers or any other endocrine tumors. Her
review of systems was remarkable for fatigue, nasal congestion, and cough with greenish sputum production
over the few weeks prior to presentation. Her physical
examination was significant only for a blood pressure of
120/77 mmHg, a heart rate of 96 beats per minute, and
a 2/6 systolic murmur over the precordial area.
Our patient had significantly elevated levels of plasma
metanephrine at 14.5 nmol/L (normal range: < 0.49
nmol/L), and normetanephrine at 24.3 nmol/L (normal
range: < 0.89 nmol/L). Similar to reports in the literature
[9], she also had an increased white blood cell count
(WBC) of 13.3 k/mm 3 (normal range: 3.8-9.8 k/mm 3 )
and a platelet count of 629 k/mm3 (normal range: 140440 k/mm3). Her other endocrine studies showed a moderately elevated plasma renin level of 21.5 ng/ml/hr (normal range: 0.65-5.0 ng/ml/hr), abnormal fasting blood
glucose (163 mg/dl) and hemoglobin-A1C (HbA1C)
(6.8%). Her aldosterone and thyroid-stimulating hormone
levels were within normal limits. She had no detectable
cardiolipin antibodies, antinuclear antibody, factor V Leiden, or prothrombin gene mutation and her rheumatoid
factor (RF) was within normal limits. Her homocysteine
level was mildly elevated at 14 umol/L (normal range: <
10.4 umol/L). The DNA analysis for methylenetetrahydrofolate reductase (MTHFR) showed a heterozygous
mutation for C677T and A1298C.
Based on the above data, our patient was diagnosed
with pheochromocytoma and treatment with phenoxybenzamine at 10 mg once a day with gradual dose titration to 30 mg three times a day was initiated. The
increased uptake of the right lower lobe of the lung on
a PET scan raised the question of a metastatic lesion.
Our patient experienced symptoms of cough, nasal congestion and green sputum production two to three
weeks prior to presentation to the outside hospital. She
likely had pneumonia at that time. Pneumonia may
cause increased uptake on a PET scan as well. Nevertheless, a (123)I- metaiodobenzylguanidine ( 123 I-MIBG)
scan was indicated to further differentiate between
metastasis and pneumonia. Her 123I-MIBG scan revealed
intense uptake only in the left abdominal mass excluding the lung mass being metastatic (Figure 1).
Six weeks after initiating anticoagulation, the intracardiac mass was no longer present on repeat echocardiogram. The adrenal mass was removed by laparoscopy
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Figure 1 123I-MIBG scan showing intensive uptake in the adrenal mass but no uptake in the lung. A 123I-MIBG scan was obtained to
determine whether the left adrenal mass and right lung mass are pheochromocytoma. Shown are the frontal and back views of the total body
scan at 72 hours. Significantly increased uptake is seen in the left adrenal lesion. No uptake was found in the lung. Physiological uptake is seen
in the salivary glands, heart and liver. 123I-MIBG is renally excreted and is visible in the bladder.

without complication. The surgical pathology report
confirmed the diagnosis of a pheochromocytoma with
the presence of vascular invasion by tumor (Figure 2).
Six weeks post-operatively, repeat plasma metanephrine
and normetanephrine levels were normal at < 0.2 nmol/
L and 0.72 nmol/L and they remained normal at followup five months later (metanephrine < 0.2 nmol/L and
normetanephrine 0.85 nmol/L). The other laboratory
abnormalities such as HbA1C, fasting blood glucose,
renin, platelet, and WBC all returned to normal. A few
months after surgery, a follow-up chest X-ray showed
no evidence of a lung mass. Our patient did not experience any more “spells.”

Discussion
In this report, we describe a patient presenting with left
arm numbness, who was later discovered to have left
ventricular thrombus, left axillary arterial thrombus and
a large left adrenal pheochromocytoma. Her presentation is unusual in that she had a thrombolic event
before the diagnosis of pheochromocytoma.
Cardiac thrombosis generally occurs as a result of
decreased ventricular contraction in the setting of anterior or apical wall myocardial infarction. It could also
happen in patients with normal ventricular contraction
in the setting of a hypercoagulative state, such as in
patients with cancer. It is often a result of inflammatory

cytokines (tumor necrosis factor, interferon-g), coagulation proteins (tissue factor and factor VIII), and procoagulants secreted by tumor cells [10]. It generally
occurs late in the progression of carcinomas and is considered a poor prognostic sign.
Thrombosis occurring in patients with pheochromocytoma has been reported previously in only a few cases
[3-8]. In one report, diffuse venous thromboses occurred
in a patient with malignant pheochromocytoma, multiple metastasis and polycythemia [5]. In another case,
central venous thrombosis occurred in conjunction with
pheochromocytoma and diabetes insipidus [6]. Additionally, a left ilio-femoral venous thrombosis was reported
in a patient with pheochromocytoma within the organ
of Zuckerkandl [7]. Besides venous thrombosis, cardiac
thrombosis has been reported in only three cases. One
patient presented with shortness of breath, a left ventricular mass and later developed a left frontal lobe infarct
[3]. During cardiac surgery to explore the intracardiac
mass, significant blood pressure fluctuation was noted
and surgery had to be aborted. This patient was later
found to have a 10 cm intra-adrenal mass. In another
case, a patient with medullary thyroid cancer and adrenal pheochromocytoma developed a left ventricular
mass which was proven surgically to be a thrombus and,
similar to our patient, there was no evidence of ventricular wall contraction abnormalities [4]. The most
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Figure 2 Histological views of the resected adrenal tumor and its intravascular invasion. A. High power (400 ×) view of the resected
adrenal tumor. The resected adrenal pheochromocytoma shows chromaffin cells with a classic nested and trabecular architecture. Other
characteristic morphologic features include nuclear enlargement and hyperchromasia with cytoplasm that is both oncocytic (pink and granular)
in some cells and basophilic (blue) in others. B. Intra-vascular invasion of tumor (400 ×). Pheochromocytoma cells seen within a blood vessel.
Vascular invasion is not a reliable indication of a malignant pheochromocytoma. Only metastatic disease to regional lymph nodes or distant sites
(most commonly ribs, spine, liver and lung) will define this tumor as a malignant lesion.
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recently reported pheochromocytoma case described a
patient with a large left ventricular thrombus and a 7
cm right adrenal mass [8]. Unfortunately, without
prompt anticoagulation, the patient developed systemic
embolization leading to kidney infarction and lower
extremity infarction requiring bilateral below-the-knee
amputation. In review of the above cases, definite underlying coagulation defects were rarely identified, whereas
erythropoietin, pro-coagulant and serotonin secreted by
the pheochromocytoma are postulated to be contributing factors. Interestingly, in some of the cases where
surgery was possible, recurrence of thrombosis was not
reported after resection of the pheochromocytoma.
Therefore, it is likely that catecholamines and other hormones, cytokine or factors secreted by pheochromocytoma may play an important role in the pathogenesis of
concurrent thrombosis and pheochromocytoma when a
predisposing coagulation disorder is not identified.
The possibility of an intracardiac mass being pheochromocytoma was also entertained in our patient.
Intracardiac pheochromocytoma is very rare. In a report
of 32 cases, 19 cases were in the left atrium, seven in
the inter-atrial septum and the remaining six on the
anterior surface of the heart [11]. None of them were in
the left ventricle. In another report, pheochromocytoma
were found on the left atrial surface, the atrio-ventricular groove, the left or right atrial cavity, the aorto-pulmonary window and the aortic root [12]. A
pheochromocytoma has not been reported in the left
ventricle. The fact that the intracardiac mass in our
patient resolved following anticoagulation and was negative on the 123I-MIBG scan supported the diagnosis of a
thrombus rather than intracardiac pheochromocytoma.
The thrombosis in our patient may be multi-factorial,
but pheochromocytoma probably played an important
role. It has been reported that platelet aggregation is
increased in patients with a pheochromocytoma [13,14].
This may predispose a patient to form thrombi in lowflow areas and increase acute coronary events. However,
moderately elevated platelet counts (less than 1000 k/
mm3) are often not considered a significant risk factor.
It is unknown whether moderately elevated platelet
counts combined with a significantly elevated catecholamine level may significantly increase the risk of thrombosis. In this case, the platelet elevation could be
reactive as it was only transiently elevated and it
returned to normal at the time of presentation to our
endocrine clinic. Oral contraceptives are associated with
a two- to six-fold increased relative risk of developing
venous thromboembolic events [15]. Atherosclerotic
events such as stroke and myocardial infarction are also
increased in those who use oral contraceptives [16,17].
However, to the best of our knowledge there have been
no reports of patients on oral contraceptives developing
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a ventricular thrombus without myocardial infarction. In
addition, the risk of thrombosis induced by oral contraceptives is highest in the first year of use [16,17] and
the risk decreases with duration of use [18]. Therefore,
oral contraceptives are less likely to be a major cause of
our patient’s ventricular and arterial thrombus, considering she has arterial but not venous thrombosis and
thrombosis occurred after a number of years of oral
contraceptive pill use. The association of hyperhomocysteinemia, a possible result of MTHFR mutation, with
arterial vascular diseases or venous thrombosis is controversial [19-22]. The MTHFR defect, when combined
with additional thrombophilic risk factors, is likely to
increase the risk of venous thrombosis, especially for a
patient with a homozygous mutation. The effect is
uncertain when no additional risk factors are present
and when the homocysteine level is only mildly elevated
(< 30 umol/L) [21]. As far as we know, no studies have
reported the association of a ventricular thrombus with
MTHFR mutation. Furthermore, the mildly abnormal
homocysteine level (14 umol/L) obtained on our patient
was not a fasting value, therefore it is not very useful
considering homocysteine level could be affected by
dietary protein intake. Thus, the heterozygous mutation
for MTHFR our patient has is unlikely to contribute significantly to her arterial and ventricular thrombosis.
Although there is no direct proof that pheochromocytoma caused thrombosis in this patient, it probably contributed significantly to this process based on the
aforementioned reasons. MTHFR heterozygous mutation
and oral contraceptives may have contributed to this
process but the likelihood is low. Appropriate anti-coagulation is essential for patients with pheochromocytoma and thrombosis to prevent devastating outcomes.

Conclusion
We report a case of pheochromocytoma uniquely presenting with left ventricular thrombus and left axillary
artery thrombus. This case highlights the complexity of
managing patients with pheochromocytoma, and presents the possible association of pheochromocytoma
with arterial thrombosis. Knowledge of this association
and the potential for embolic events will educate clinicians to be more vigilant about the pro-thrombosis state
in patients with pheochromocytoma. Anticoagulation
regimen should be employed to avoid devastating
embolic events and therefore reduce morbidity and
mortality. This will help to make a difference in the
management of patients with pheochromocytoma.
Patient’s perspective

The heart palpitations were the first symptoms I
noticed. Those began in December 2001. By February
2002, I experienced my first migraine along with the
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palpitations. The migraine lasted several hours. I began
taking oral contraceptives again in 2002 and the frequency and duration of the migraines diminished
although not completely.
My symptoms were easy to ignore until the summer
of 2005 when the “cluster” headaches started. These
were different than migraines in that they started at the
base of my skull on the right side and did not respond
to over-the-counter pain relievers. Also during that
time, I noticed my blood pressure was higher than normal. Historically, my blood pressure was in the low-tonormal range until about 2005, typically around 112/60.
I had my blood pressure checked about once a year during routine physicals required to renew my birth control
prescription. From 2005-2007, my blood pressure steadily rose. Beginning in 2006, I was treated with lisinopril
and hydrochlorothiazide and later, atenolol. Once treatment began, the cluster headaches diminished.
Although the headaches diminished with the hypertension treatment, other symptoms became more apparent. Along with the “pounding” heart palpitations, I
began experiencing a very definite progression of symptoms; pounding heart, a burning sensation around my
heart and chest, cold sweats, nausea, vomiting. The
burning and numbness would then creep up from my
chest to the back of my neck and head and extend up. I
would then experience excruciating headaches from the
top of my head to behind my eyes. I called it “riding
the wave” because they generally only lasted a few seconds to a few minutes and once the headache subsided,
I felt fine. I could sometimes predict them when I
noticed blind spots in my vision, the precursor to a
migraine.
After the removal of the pheochromocytoma, the only
negative health issues were an upper gastrointestinal
bleed due to a Dieulafoy’s Lesion, that occurred two
weeks post op. Restenosis of my stent occurred in January 2008 which was discovered after my left arm went
numb again. As a result of the blockage, my doctor has
continued a prescription for Coumadin (warfarin) as
well as 81 mg of aspirin. I also take one tablet of Folgard, a folic acid supplement. Other than those two incidents, I have felt fine and life is back to normal.
Consent

Written informed consent was obtained from the patient
for publication of this case report and any accompanying images. A copy of the written consent is available
for review by the Editor-in-Chief of this journal.
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